Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OTLK Outlook Therapeutics, Inc.

休市中 05-01 16:00:00 EDT

0.2622

+0.0122

+4.88%

盘后0.2576

-0.0046-1.75%

19:55 EDT

最高0.2705	最低0.2441	成交量406.16万
今开0.2576	昨收0.2500	日振幅10.56%
总市值3,173万	流通市值2,753万	总股本1.21亿
成交额104.76万	换手率3.87%	流通股本1.05亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.2622,"timestamp":1777665600000,"preClose":0.25,"halted":0,"volume":4061566,"hourTrading":{"tag":"盘后","latestPrice":0.2576,"preClose":0.2622,"latestTime":"19:55 EDT","volume":158210,"amount":40746.5622,"timestamp":1777679726335,"change":-0.0046,"changeRate":-0.017544,"amplitude":0.074371},"delay":0,"changeRate":0.048799999999999955,"floatShares":105000000,"shares":121000000,"eps":-2.89,"marketStatus":"休市中","change":0.0122,"latestTime":"05-01 16:00:00 EDT","open":0.2576,"high":0.2705,"low":0.2441,"amount":1047581.0351764001,"amplitude":0.1056,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.89,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777881600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.25,"preHourTrading":{"tag":"盘前","latestPrice":0.2569,"preClose":0.25,"latestTime":"09:26 EDT","volume":81348,"amount":20838.975730560003,"timestamp":1777642005286,"change":0.0069,"changeRate":0.0276,"amplitude":0.0548},"postHourTrading":{"tag":"盘后","latestPrice":0.2576,"preClose":0.2622,"latestTime":"19:55 EDT","volume":158210,"amount":40746.5622,"timestamp":1777679726335,"change":-0.0046,"changeRate":-0.017544,"amplitude":0.074371},"volumeRatio":0.9967129759915154,"impliedVol":0.4946,"impliedVolPercentile":0.239},"requestUrl":"/m/hq/s/OTLK","defaultTab":"news","newsList":[{"id":"1182483377","title":"Outlook Therapeutics宣布500万美元纳斯达克规则下市价定价注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1182483377","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182483377?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:30","pubTimestamp":1776861036,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.  今日披露了一项重要融资安排。该公司已达成协议，将通过注册直接发行的方式募集500万美元资金。此次发行定价严格遵循纳斯达克市场的相关规定，采用市价定价机制。这项融资举措标志着Outlook Therapeutics在资本运作方面迈出关键一步。根据纳斯达克规则，此次发行符合市场化定价原则。此次融资所得将用于推进公司核心管线的临床开发及一般营运资金需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107650089","title":"Outlook Therapeutics完成与FDA就ONS-5010/Lytenava™（贝伐珠单抗-Vikg）的联邦争议解决会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1107650089","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107650089?lang=zh_cn&edition=full","pubTime":"2026-04-21 21:06","pubTimestamp":1776776777,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 已顺利完成与美国食品药品监督管理局（FDA）针对眼科药物ONS-5010/Lytenava™（贝伐珠单抗-Vikg）的联邦争议解决（FDR）会议。此次关键性会议标志着该药物在寻求监管批准路径上的一个重要里程碑。公司正积极推动这一潜在疗法，旨在为湿性年龄相关性黄斑变性（wet AMD）患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164642417","title":"Outlook Therapeutics宣布FDA已受理关于Ons-5010/Lytenava™（贝伐珠单抗-Vikg）的正式争议解决申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1164642417","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164642417?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:50","pubTimestamp":1775566215,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.披露，美国食品药品监督管理局（FDA）已正式接受该公司针对其核心候选药物Ons-5010/Lytenava™（贝伐珠单抗-Vikg）所提交的正式争议解决请求。这一进展标志着公司在推动该眼科疗法获批的进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139966539","title":"Outlook Therapeutics完成500万美元公开发行募资","url":"https://stock-news.laohu8.com/highlight/detail?id=1139966539","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139966539?lang=zh_cn&edition=full","pubTime":"2026-03-26 04:07","pubTimestamp":1774469224,"startTime":"0","endTime":"0","summary":"新泽西州艾斯林2026年3月25日电——专注于提升视网膜疾病治疗标准生物制药企业Outlook Therapeutics, Inc.今日宣布，已完成此前公布的2000万股普通股及配套认股权证公开发行。每份认股权证可额外认购1股普通股，发行单元定价为0.25美元。认股权证行权价每股0.25美元，即日生效，有效期五年。本次发行扣除承销费用前的总收益为500万美元。若认股权证全部以现金行权，公司有望再获约500万美元资金注入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4099","BK4007","BK4604","03160","BK4139","LENZ","BK4585","BK4588","BK4539","BK4555","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173210935","title":"Outlook Therapeutics公司利用新票据收益偿还旧债，现有票据本金及利息余额为1080万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173210935","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173210935?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664512,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics公司宣布将利用新发行票据所筹集的资金，用于偿还部分现有票据债务。经此操作后，该公司现有票据未偿还本金及利息余额仍达1080万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126487152","title":"Outlook Therapeutics将继续与FDA沟通 就确认性证据及后续路径寻求共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1126487152","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126487152?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:17","pubTimestamp":1772745431,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc.宣布，将持续与美国食品药品监督管理局（FDA）保持密切对话，旨在进一步明确监管机构对确认性证据要求的具体立场，并共同商定最合适的后续发展路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151191468","title":"Outlook Therapeutics与FDA就ONS-5010/Lytenava™（贝伐珠单抗-Vikg）召开A类会议后发布最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1151191468","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151191468?lang=zh_cn&edition=full","pubTime":"2026-03-06 05:15","pubTimestamp":1772745351,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.近日披露了与美国食品药品监督管理局就眼科药物ONS-5010/Lytenava举行A类会议后的关键动态。此次会议聚焦于该药物用于治疗湿性年龄相关性黄斑变性的监管路径，双方就后续申报策略达成重要共识。公司表示，与FDA的深入交流进一步明确了生物制品许可申请所需补充的数据要求及临床开发计划。此次沟通为ONS-5010/Lytenava的审评进程提供了更清晰的指引，有望加速其商业化进程。Outlook Therapeutics强调将继续与FDA保持密切协作，积极推进药物上市准备工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147633088","title":"Outlook Therapeutics合作推进欧洲商业化战略，Lytenava预计2027年在瑞士上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1147633088","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147633088?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:02","pubTimestamp":1771509746,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.通过合作伙伴关系加速其欧洲市场扩张计划，旗下创新药物Lytenava有望于2027年正式登陆瑞士市场。这一战略部署标志着公司在欧洲商业化布局取得重要进展，为未来业绩增长注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178881233","title":"Outlook Therapeutics与Mediconsult Ag达成瑞士独家分销协议 扩大欧洲版图","url":"https://stock-news.laohu8.com/highlight/detail?id=1178881233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178881233?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:02","pubTimestamp":1771509725,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布与Mediconsult Ag签署独家商业分销协议，将旗下眼科药物Lytenava™（贝伐珠单抗γ）引入瑞士市场。这一战略合作标志着公司在欧洲业务布局的进一步扩展，有望提升其生物类似药产品在欧洲关键市场的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612978184","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.78%报0.462美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612978184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612978184?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:30","pubTimestamp":1771338641,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时30分，Outlook Therapeutics, Inc.股票出现异动，股价快速下挫5.78%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.、Kalaris Therapeutics, Inc.涨幅较大，Ernexa Therapeutics Inc.、Polaryx Therapeutics, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为60.99%、26.50%、26.09%，振幅较大的相关个股有Alpha Cognition Inc.、Igc Pharma, Inc.、Onconetix, Inc.，振幅分别为10.41%、10.12%、6.97%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc是一家临床阶段生物制药公司，专注于开发和商业化ONS-5010，这是一种用于各种眼科适应症的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223041a4ad855c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223041a4ad855c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","OTLK","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145450453","title":"Outlook Therapeutics Inc：拟继续与FDA合作 寻求解决额外验证性证据要求的可行路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1145450453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145450453?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:50","pubTimestamp":1770817840,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc表示，计划继续与美国食品药品监督管理局（FDA）保持密切合作，共同探索可行路径，以解决FDA提出的关于补充提供额外验证性证据的要求。公司致力于推进相关程序，确保符合监管标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603364809","title":"Outlook Therapeutics, Inc.盘中异动 早盘急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603364809","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603364809?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:37","pubTimestamp":1768487871,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时37分，Outlook Therapeutics, Inc.股票出现异动，股价急速跳水5.11%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Cns Pharmaceuticals, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Immunitybio, Inc.涨幅较大，Gt Biopharma, Inc.、Applied Therapeutics, Inc.、Genprex, Inc.较为活跃，换手率分别为50.97%、42.84%、20.56%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 、60 Degrees Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.，振幅分别为64.67%、21.43%、15.65%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc是一家临床阶段生物制药公司，专注于开发和商业化ONS-5010，这是一种用于各种眼科适应症的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223751a4c81db0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223751a4c81db0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","BK4139","BK4007","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141589852","title":"Outlook Therapeutics任命Laura Cantrell为战略规划与业务拓展副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1141589852","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141589852?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:36","pubTimestamp":1767706580,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc.近日宣布一项重要人事任命——Laura Cantrell正式加入公司管理层，担任企业战略与业务发展副总裁一职。此次任命将强化公司在眼科生物制剂领域的战略布局，Cantrell女士将主导全球商业合作机会的挖掘与战略规划体系的优化。首席执行官Russell Trenary表示：\"Laura在生物制药商业拓展领域的卓越履历，与公司现阶段发展需求高度契合。\"据悉，Cantrell将直接向Trenary汇报工作，并参与制定公司长期发展战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195317623","title":"Outlook Therapeutics公司：FDA尚未明确何种验证性证据可被接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1195317623","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195317623?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:17","pubTimestamp":1767215830,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics公司近日面临监管不确定性，美国食品药品监督管理局（FDA）至今未就公司提交的药品申请给出明确指引。监管机构尚未表态何种类型的验证性临床证据能够满足审批要求，这为该公司核心产品的上市路径增添了变数。\n当前局面反映出生物科技企业在创新药审评过程中常见的挑战。FDA的沉默意味着Outlook Therapeutics需要继续投入资源探索符合监管要求的证据体系，而这一过程可能影响产品商业化的时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145824968","title":"Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™（贝伐珠单抗-Vikg）审评的最新监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1145824968","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145824968?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:16","pubTimestamp":1767215790,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 近日披露了旗下核心产品Ons-5010/Lytenava™（贝伐珠单抗-Vikg）针对湿性年龄相关性黄斑变性（湿性AMD）适应症的最新监管动态。该公司已接获美国食品药品监督管理局（FDA）就该项新药申请（BLA）的审评更新通知，标志着该疗法在美获批进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174726101","title":"Outlook Therapeutics Inc：Ons-5010如获批准，将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1174726101","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174726101?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:31","pubTimestamp":1763040691,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc：Ons-5010如获批准，将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518042662","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.34%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518042662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518042662?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:56","pubTimestamp":1741633004,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时56分，Outlook Therapeutics, Inc.股票出现异动，股价急速下跌5.34%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为6148.90%、3854.04%、1014.79%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517698565","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大涨5.28%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517698565","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517698565?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:19","pubTimestamp":1741119563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时19分，Outlook Therapeutics, Inc.股票出现异动，股价急速上涨5.28%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516688296","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516688296?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:02","pubTimestamp":1741032163,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时02分，Outlook Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4576.31%、211.77%、182.41%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514566375","title":"Outlook Therapeutics, Inc.盘中异动 早盘快速拉升5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514566375?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:53","pubTimestamp":1740754380,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时53分，Outlook Therapeutics, Inc.股票出现异动，股价急速上涨5.80%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1679},{"period":"1month","weight":0.2486},{"period":"3month","weight":-0.4037},{"period":"6month","weight":-0.7919},{"period":"1year","weight":-0.833},{"period":"ytd","weight":-0.8341}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0998},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.0566},{"period":"1year","weight":0.2904},{"period":"ytd","weight":0.0568}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Outlook Therapeutics, Inc.于2010年1月5日在新泽西州注册成立。该公司是一家生物制药公司，在欧盟或欧盟、英国或英国率先获得ONS-5010/LYTENAVA（贝伐珠单抗-gamma）眼科制剂上市许可，用于治疗湿性年龄相关性黄斑变性，或湿性AMD。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.143641},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}